REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 189 filers reported holding REATA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.71 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $1,430,000 | -74.8% | 54,226 | -3.9% | 0.00% | -75.0% |
| Q3 2021 | $5,680,000 | -28.9% | 56,455 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $7,990,000 | -11.9% | 56,455 | -37.9% | 0.01% | -14.3% |
| Q1 2021 | $9,065,000 | +42.6% | 90,923 | +76.8% | 0.01% | +40.0% |
| Q4 2020 | $6,358,000 | +29.3% | 51,431 | +1.9% | 0.01% | +25.0% |
| Q3 2020 | $4,918,000 | -40.6% | 50,484 | -4.9% | 0.00% | -50.0% |
| Q2 2020 | $8,282,000 | +13.5% | 53,081 | +5.0% | 0.01% | -11.1% |
| Q1 2020 | $7,300,000 | -49.4% | 50,577 | -28.3% | 0.01% | -30.8% |
| Q4 2019 | $14,422,000 | +384.0% | 70,547 | +90.1% | 0.01% | +333.3% |
| Q3 2019 | $2,980,000 | -3.5% | 37,119 | +13.4% | 0.00% | -25.0% |
| Q2 2019 | $3,089,000 | +9.5% | 32,735 | -0.8% | 0.00% | +33.3% |
| Q1 2019 | $2,821,000 | +76.4% | 33,001 | +15.8% | 0.00% | +50.0% |
| Q4 2018 | $1,599,000 | +459.1% | 28,503 | +713.7% | 0.00% | – |
| Q3 2018 | $286,000 | – | 3,503 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |